(19)
(11) EP 2 212 700 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.10.2011 Bulletin 2011/41

(45) Mention of the grant of the patent:
24.08.2011 Bulletin 2011/34

(21) Application number: 08851789.1

(22) Date of filing: 18.11.2008
(51) International Patent Classification (IPC): 
G01N 33/574(2006.01)
(86) International application number:
PCT/EP2008/009733
(87) International publication number:
WO 2009/065551 (28.05.2009 Gazette 2009/22)

(54)

METHOD OF ASSESSING COLORECTAL CANCER FROM A STOOL SAMPLE BY USE OF THE MARKER COMBINATION CALPROTECTIN AND HEMOGLOBIN/HAPTOGLOBIN COMPLEX

VERFAHREN ZUR BEURTEILUNG VON KOLOREKTALEM KREBS ANHAND EINER STUHLPROBE DURCH VERWENDUNG EINER MARKER-KOMBINATION AUS CALPROTECTIN UND EINEM HÄMOGLOBIN/HAPTOGLOBIN-KOMPLEX

PROCÉDÉ DE DÉTECTION DU CANCER COLORECTAL À PARTIR D'UN ÉCHANTILLON DE SELLES AU MOYEN D'UNE COMBINAISON DE MARQUEURS ASSOCIANT LA CALPROTECTINE ET LE COMPLEXE HÉMOGLOBINE/HAPTOGLOBINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 20.11.2007 EP 07022448

(43) Date of publication of application:
04.08.2010 Bulletin 2010/31

(73) Proprietors:
  • Roche Diagnostics GmbH
    68305 Mannheim (DE)
    Designated Contracting States:
    DE 
  • F.Hoffmann-La Roche AG
    4070 Basel (CH)
    Designated Contracting States:
    AT BE BG CH CY CZ DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR 

(72) Inventors:
  • KARL, Johann
    82380 Peissenberg (DE)
  • GARCZAREK, Ursula
    44309 Dortmund (DE)
  • WILD, Norbert
    82538 Geretsried (DE)


(56) References cited: : 
WO-A-98/20355
JP-A- 2004 251 851
 WO-A-2007/134779
   
  • HOFF G ET AL: "Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT)" September 2004 (2004-09), GUT, VOL. 53, NR. 9, PAGE(S) 1329-1333 , XP000910339 ISSN: 0017-5749 the whole document
  • ROSETH A G ET AL: "ASSESSMENT OF THE NEUTROPHIL DOMINATING PROTEIN CALPROTECTIN IN FECES A METHODOLOGIC STUDY" 1992, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, VOL. 27, NR. 9, PAGE(S) 793-798 , XP009110340 ISSN: 0036-5521 the whole document
  • LIMBURG PAUL J ET AL: "Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia." AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 98, no. 10, October 2003 (2003-10), pages 2299-2305, XP002509148 ISSN: 0002-9270
  • GILBERT J A ET AL: "FECAL MARKER VARIABILITY IN COLORECTAL CANCER: CALPROTECTIN VERSUS HEMOGLOBIN" 1 January 1996 (1996-01-01), SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, XX, XX, PAGE(S) 1001 - 1005 , XP002053475 ISSN: 0036-5521 the whole document
  • SIEG A ET AL: "DETECTION OF COLORECTAL NEOPLASMS BY THE HIGHLY SENSITIVE HEMOGLOBIN-HAPTOGLOBIN COMPLEX IN FECES" 1 December 1999 (1999-12-01), INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, SPRINGER VERLAG, BERLIN, DE, PAGE(S) 267 - 271 , XP001182520 ISSN: 0179-1958 the whole document
  • KARL JOHANN ET AL: "Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers." CLINICAL GASTROENTEROLOGY AND HEPATOLOGY : THE OFFICIAL CLINICAL PRACTICE JOURNAL OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION OCT 2008, vol. 6, no. 10, October 2008 (2008-10), pages 1122-1128, XP009110343 ISSN: 1542-7714
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).